{
    "id": 30985,
    "fullName": "CHEK2 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CHEK2 amplification indicates an increased number of copies of the CHEK2 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 11200,
        "geneSymbol": "CHEK2",
        "terms": [
            "CHEK2",
            "CDS1",
            "CHK2",
            "hCds1",
            "HuCds1",
            "LFS2",
            "PP1425",
            "RAD53"
        ]
    },
    "variant": "amp",
    "createDate": "09/16/2019",
    "updateDate": "09/16/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19861,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment inhibited tumor growth but did not induce regression in a patient-derived xenograft (PDX) model of ovarian cancer harboring wild-type ATM, CHEK2 amplification, TP53 and BRCA1 mutations, and RB1 and XRCC3 deletions (PMID: 31699977).",
            "molecularProfile": {
                "id": 34748,
                "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19863,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of ovarian cancer harboring wild-type ATM, CHEK2 amplification, TP53 and BRCA1 mutations, and RB1 and XRCC3 deletions (PMID: 31699977).",
            "molecularProfile": {
                "id": 34748,
                "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19859,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment induced tumor regression in a patient-derived xenograft (PDX) model of ovarian cancer harboring wild-type ATM, CHEK2 amplification, TP53 and BRCA1 mutations, and RB1 and XRCC3 deletions (PMID: 31699977).",
            "molecularProfile": {
                "id": 34748,
                "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del"
            },
            "therapy": {
                "id": 8902,
                "therapyName": "AZD7648 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 33281,
            "profileName": "CHEK2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34555,
            "profileName": "ATM wild-type BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34748,
            "profileName": "BRCA1 mut CHEK2 amp RB1 del TP53 mut XRCC3 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}